Lessons We Have Learned Regarding Seroprevalence in High and Low SARS-CoV-2 Contexts in Greece before the Omicron Pandemic Wave.
Greece
antibody testing
semi-closed community
seroprevalence
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
17 05 2022
17 05 2022
Historique:
received:
24
03
2022
revised:
08
05
2022
accepted:
13
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
Antibody seroprevalence in rural communities remains poorly investigated. We compared the SARS-CoV-2 seroprevalence in two Greek communities in June and July 2021 after the end of the Delta-driven pandemic wave that started in November 2020. One community was affected worse than the other. The SARS-CoV-2 IgG II Quant method (Architect, Abbott, IL, USA) was used for antibody testing. We found a high rate of SARS-CoV-2 seropositivity in both communities, approaching 77.5%. In the area with a higher burden of COVID-19, Malesina, seropositivity was achieved with vaccine-acquired and naturally acquired immunity, whereas in the low-burden context of Domokos, the high rates of seropositivity were achieved mainly with vaccination. Previously infected individuals were less likely to be vaccinated than previously uninfected adults. The antibody titers were significantly higher in previously infected, vaccinated participants than in unvaccinated ones. In total, 4% and 10% of the unvaccinated population were diagnosed seropositive for the first time while not knowing about the previous infection. Age and gender did not impact antibody titers in high- or low-burden contexts. Before the Omicron pandemic wave, herd immunity was reached in different contexts in Greece. Higher antibody titers were measured in infected vaccinated individuals than in infected unvaccinated ones.
Sections du résumé
BACKGROUND
Antibody seroprevalence in rural communities remains poorly investigated. We compared the SARS-CoV-2 seroprevalence in two Greek communities in June and July 2021 after the end of the Delta-driven pandemic wave that started in November 2020. One community was affected worse than the other.
METHODS
The SARS-CoV-2 IgG II Quant method (Architect, Abbott, IL, USA) was used for antibody testing.
RESULTS
We found a high rate of SARS-CoV-2 seropositivity in both communities, approaching 77.5%. In the area with a higher burden of COVID-19, Malesina, seropositivity was achieved with vaccine-acquired and naturally acquired immunity, whereas in the low-burden context of Domokos, the high rates of seropositivity were achieved mainly with vaccination. Previously infected individuals were less likely to be vaccinated than previously uninfected adults. The antibody titers were significantly higher in previously infected, vaccinated participants than in unvaccinated ones. In total, 4% and 10% of the unvaccinated population were diagnosed seropositive for the first time while not knowing about the previous infection. Age and gender did not impact antibody titers in high- or low-burden contexts.
CONCLUSIONS
Before the Omicron pandemic wave, herd immunity was reached in different contexts in Greece. Higher antibody titers were measured in infected vaccinated individuals than in infected unvaccinated ones.
Identifiants
pubmed: 35627648
pii: ijerph19106110
doi: 10.3390/ijerph19106110
pmc: PMC9140933
pii:
doi:
Substances chimiques
Viral Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J R Soc Med. 2022 Feb;115(2):76-77
pubmed: 35176907
Am J Clin Pathol. 2021 Mar 15;155(4):471-472
pubmed: 33399182
N Engl J Med. 2022 Mar 31;386(13):1207-1220
pubmed: 35172051
J Med Virol. 2022 Jan;94(1):24-25
pubmed: 34491592
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Int J Environ Res Public Health. 2021 Jan 04;18(1):
pubmed: 33406780
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Cell. 2022 Mar 17;185(6):1025-1040.e14
pubmed: 35148837
J Clin Med. 2021 Jun 23;10(13):
pubmed: 34201868
JAMA Netw Open. 2021 Dec 1;4(12):e2137257
pubmed: 34905008
Nat Rev Immunol. 2020 Oct;20(10):583-584
pubmed: 32908300
Lancet Reg Health West Pac. 2021 Dec;17:100317
pubmed: 34841381
Nat Commun. 2021 Apr 9;12(1):2117
pubmed: 33837204
Nature. 2022 Apr;604(7904):141-145
pubmed: 35168246
Int J Environ Res Public Health. 2021 Dec 31;19(1):
pubmed: 35010667
Nat Med. 2020 Aug;26(8):1171-1172
pubmed: 32719488
J Microbiol Immunol Infect. 2021 Feb;54(1):12-16
pubmed: 32425996
Nat Med. 2022 May;28(5):1072-1082
pubmed: 35165453
Lancet Respir Med. 2021 Dec;9(12):1450-1466
pubmed: 34688434
Ethics Med Public Health. 2022 Apr;21:100761
pubmed: 35097181